ImmunityBio, Inc. (IBRX)

業務介紹

ImmunityBio, Inc.是一家臨床階段的生物技術公司，致力於開發治療癌症和傳染病的療法和疫苗。它提供免疫療法和細胞療法平台，包括抗體細胞因子融合蛋白、合成免疫調節劑、疫苗技術、自然殺傷細胞和適應性（T細胞）免疫系統。該公司還開發了用於治療液體和固體腫瘤的治療劑，這些藥物正在進行II或III期臨床試驗，包括膀胱、胰臟和肺癌，以及SARS-CoV-2和HIV等病原體。它與美國國家癌症研究所、美國國家聾啞和溝通障礙研究所以及Amyris, Inc.等機構有合作協議；並與CytRx Corporation、EnGeneIC Pty Limited、GlobeImmune, Inc.、Infectious Disease Research Institute、Sanford Health、Shenzhen Beike Biotechnology Co. Ltd.、Sorrento Therapeutics, Inc.和Viracta Therapeutics, Inc.等公司簽訂了許可協議。該公司成立於2014年，總部位於加利福尼亞州聖地亞哥。

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.

公司網址

https://immunitybio.com